Involvement of estrogen receptor β in androgen receptor‑induced growth inhibition in prostate cancer PC‑3 cells

Xiao,Long; Xiao,Minhui; Gao,Linbo; Xu,Wanchao

doi:10.3892/ol.2017.6544

Involvement of estrogen receptor β in androgen receptor‑induced growth inhibition in prostate cancer PC‑3 cells

Authors:
- Long Xiao
- Minhui Xiao
- Linbo Gao
- Wanchao Xu
View Affiliations

Affiliations: Department of Urology, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, Yunnan 650041, P.R. China, Laboratory of Molecular and Translational Medicine, West China Institute of Women and Children's Health, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: July 8, 2017 https://doi.org/10.3892/ol.2017.6544
Pages: 2796-2802
Copyright: © Xiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have suggested that changes in sex hormone receptor expression may be associated with the initiation and progression of prostate cancer (PCa). Therefore, the present study aimed to investigate the association and possible pathways between two sex hormone receptors and PCa by measuring the expression levels of the androgen receptor (AR) and the estrogen receptor subtypes alpha (ERα) and beta (ERβ) in prostatic cancer PC‑3 cell lines. The pcDNA3.1‑hERβ plasmid was transfected into PC‑3 cell lines. The expression levels of AR, ERα and ERβ were detected at the mRNA level by reverse transcription‑polymerase chain reaction (RT‑PCR) and quantitative PCR (qPCR). The results demonstrated that the expression levels of AR, ERβ and ERα were downregulated to different degrees: ERβ test group vs. PC‑3 cell group (P=0.000; 95% confidence interval: 0.9803‑1.6331). ERβ and AR expression was detected continuously in the PC‑3 cells, but the expression of ERα was not. AR expression levels exhibited an upward trend whilst the expression of ERβ demonstrated a marked downward trend. There is a correlation between the expression levels of ERβ and the incidence of PCa, and ERβ may inhibit the growth of PC‑3 cell lines by regulating the expression levels of AR. ERβ may provide a novel target for PCa therapies.

View Figures

View References

1	Benjamins MR, Hunt BR, Raleigh SM, Hirschtick JL and Hughes MM: Racial disparities in prostate cancer mortality in the 50 Largest US Cities. Cancer Epidemiol. 44:125–131. 2016. View Article : Google Scholar : PubMed/NCBI
2	James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C, et al: TRAPEZE: A randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technol Assess. 20:1–288. 2016. View Article : Google Scholar : PubMed/NCBI
3	Slusarz A, Jackson GA, Day JK, Shenouda NS, Bogener JL, Browning JD, Fritsche KL, MacDonald RS, Besch-Williford CL and Lubahn DB: Aggressive prostate cancer is prevented in ERαKO mice and stimulated in ERβKO TRAMP mice. Endocrinology. 153:4160–4170. 2012. View Article : Google Scholar : PubMed/NCBI
4	Levakov AF, Kaćanski MM, Vucković N, Zivojinov M, Amidzić J and Sabo JI: The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions. Vojnosanit Pregl. 72:906–913. 2015. View Article : Google Scholar : PubMed/NCBI
5	Wang L, Zhang P, Meng X, Chen X, Xiang Z, Lin X, Liu Y, Gan W, Han X and Li D: Correlation between the germline methylation status in ERβ promoter and the risk in prostate cancer: A prospective study. Fam Cancer. 15:309–315. 2016. View Article : Google Scholar : PubMed/NCBI
6	Weihua Z, Warner M and Gustafsson JA: Estrogen receptor beta in the prostate. Mol Cell Endocrinol. 193:1–5. 2002. View Article : Google Scholar : PubMed/NCBI
7	Kumar R, Verma V, Sharma V, Jain A, Singh V, Sarswat A, Maikhuri JP, Sharma VL and Gupta G: A precisely substituted benzopyran targets androgen refractory prostate cancer cells through selective modulation of estrogen receptors. Toxicol Appl Pharmacol. 283:187–197. 2015. View Article : Google Scholar : PubMed/NCBI
8	Mahmoud AM, Al-Alem U, Ali MM and Bosland MC: Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation. J Steroid Biochem Mol Biol. 152:62–75. 2015. View Article : Google Scholar : PubMed/NCBI
9	Asgari M and Morakabati A: Estrogen receptor beta expression in prostate adenocarcinoma. Diagn Pathol. 6:612011. View Article : Google Scholar : PubMed/NCBI
10	Attia DM and Ederveen AG: Opposing roles of ERα and ERβ in the genesis and progression of adenocarcinoma in the rat ventral prostate. Prostate. 72:1013–1022. 2012. View Article : Google Scholar : PubMed/NCBI
11	Medeiros R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J and Lopees C: Steroid hormone genotypes ARStuI and ER325 are linked to the progression of human prostate cancer. Cancer Genet Cytogenet. 141:91–96. 2003. View Article : Google Scholar : PubMed/NCBI
12	Muthusamy S, Andersson S, Kim HJ, Butler R, Waage L, Bergerheim U and Gustafsson JÅ: Estrogen receptor β and 17β-hydroxysteroiddeh ydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer. Proc Natl Acad Sci USA. 108:20090–20094. 2011. View Article : Google Scholar : PubMed/NCBI
13	Signoretti S and Loda M: Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am J Pathol. 159:13–16. 2001. View Article : Google Scholar : PubMed/NCBI
14	Megas G, Chrisofos M, Anastasiou I, Tsitlidou A, Choreftaki T and Deliveliotis C: Estrogen receptor (α and β) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population. Asian J Androl. 17:98–105. 2015. View Article : Google Scholar : PubMed/NCBI
15	Lombardi AP, Pisolato R, Vicente CM, Lazari MF, Lucas TF and Porto CS: Estrogen receptor beta (ERβ) mediates expression of β-catenin and proliferation in prostate cancer cell line PC-3. Mol Cell Endocrinol. 430:12–24. 2016. View Article : Google Scholar : PubMed/NCBI
16	Royuela M, de Miguel MP, Bethencourt FR, Sánchez-Chapado M, Fraile B, Arenas MI and Paniagua R: Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol. 163:447–454. 2001. View Article : Google Scholar
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Bosland MC: Sex steroids and prostate carcinogenesis: Integrated, multifactorial working hypothesis. Ann N Y Acad Sci. 1089:168–176. 2006. View Article : Google Scholar : PubMed/NCBI
19	Thapa D and Ghosh R: Chronic inflammatory mediators enhance prostate cancer development and progression. Biochem Pharmacol. 94:53–62. 2015. View Article : Google Scholar : PubMed/NCBI
20	Alcaraz A, Hammerer P, Tubaro A, Schröder FH and Castro R: Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 55:864–873. 2009. View Article : Google Scholar : PubMed/NCBI
21	Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO and Mulder E: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 173:534–540. 1990. View Article : Google Scholar : PubMed/NCBI
22	Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
23	Suryavanshi M, Mehta A, Jaipuria J, Sharma AK, Rawal S and Seth N: Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: An Indian outlook. Urol Oncol. 33(331): e9–15. 2015.
24	Kleb B, Estécio MR, Zhang J, Tzelepi V, Chung W, Jelinek J, Navone NM, Tahir S, Marquez VE, Issa JP, et al: Differentially methylated genes and androgen receptor re-expression in small cell prostatecarcinomas. Epigenetics. 11:184–193. 2016. View Article : Google Scholar : PubMed/NCBI
25	Weihua Z, Ekman J, Almkvist A, Saji S, Wang L, Warner M and Gustafsson JA: Involvement of androgen receptor in 17beta-estradiol-induced cell proliferation in rat uterus. Biol Reprod. 67:616–623. 2002. View Article : Google Scholar : PubMed/NCBI
26	McPherson SJ, Ellem SJ, Simpson ER, Patchev V, Fritzemeier KH and Risbridger GP: Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology. 148:566–574. 2007. View Article : Google Scholar : PubMed/NCBI
27	Lau KM, LaSpina M, Long J and Ho SM: Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res. 60:3175–3182. 2000.PubMed/NCBI
28	Cheng J, Lee EJ, Madison LD and Lazennec G: Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett. 566:169–172. 2004. View Article : Google Scholar : PubMed/NCBI